Protein Aggregation Inhibitors as Disease-Modifying Therapies for Polyglutamine Diseases
Eiko N. Minakawa(National Center of Neurology and Psychiatry), Yoshitaka Nagai(Meiji University)
Cited by 52
Related Papers
Multiple candidate gene analysis identifies α-synuclein as a susceptibility gene for sporadic Parkinson's disease
|Human Molecular Genetics|2006|207
Arginine is a disease modifier for polyQ disease models that stabilizes polyQ protein conformation
|Brain|2020|38
Abnormalities in synaptic dynamics during development in a mouse model of spinocerebellar ataxia type 1
|Scientific Reports|2015|20